Search
Lunacalcipol
go.drugbank.com/drugs/DB05024InvestigationalCTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. … This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways.
Anatibant
go.drugbank.com/drugs/DB05038ExperimentalAnatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
DDP733
go.drugbank.com/drugs/DB05049InvestigationalIt is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent. … Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.
Fenretinide
go.drugbank.com/drugs/DB05076InvestigationalA synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Categories: Compounds used in a research, industrial, or household settingTetrathiomolybdate
go.drugbank.com/drugs/DB05088InvestigationalTetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It i...
Categories: Compounds used in a research, industrial, or household settingM0002
go.drugbank.com/drugs/DB05091InvestigationalIt is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.
UCB-1184197
go.drugbank.com/drugs/DB05092Investigational(now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. … It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc.
Cimicoxib
go.drugbank.com/drugs/DB05095InvestigationalCimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.